English
Insider transactions
EDGARDaxor Corporation
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-17.
- Open-market purchases (code P)
- 6 transactions, 28,941 shares
- Sum of shares × price per share: 18,970 4 without a price are not valued.
- Open-market sales (code S)
- 0 transactions, — shares
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–14 of 14
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-28 Filed 2026-09-01 | Jefferies John Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,451 | 0 | — | 26,008 | Direct (D) | No | F1
| Open filing 0001493152-26-040999 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-25 | DesRosiers Caleb Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,500 | 0 | — | 2,500 | Direct (D) | No | F1, F2
| Open filing 0001493152-26-030165 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-25 | Goudie Joy S. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,500 | 0 | — | 2,500 | Direct (D) | No | F1, F2
| Open filing 0001493152-26-030180 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-25 | Cremisi Henry D. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,500 | 0 | — | 2,500 | Direct (D) | No | F1, F2
| Open filing 0001493152-26-030175 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-25 | Feldschuh Michael Richard Director · Officer: Chief Executive Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 30,000 | 0 | — | 243,694 | Direct (D) | No | F1
| Open filing 0001493152-26-030192 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-25 | Feldschuh Jonathan Adam Director · Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,000 | 0 | — | 78,908 | Direct (D) | No | F1
| Open filing 0001493152-26-030187 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-25 | Feuer Edward Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,500 | 0 | — | 2,500 | Direct (D) | No | F1, F2
| Open filing 0001493152-26-030171 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-25 | Michel Robert J Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 12,000 | 0 | — | 33,050 | Direct (D) | No | F1
| Open filing 0001493152-26-030197 Read from the filing’s XML Dispute this row |
| 2026-04-08 Filed 2026-04-10 | Feldschuh Michael Richard Director · Officer: Chief Executive Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 1,000 | 9.07 | 9,070Derived: shares × price per share. Exact value 9070.00. | 213,694 | Direct (D) | No | — | Open filing 0001493152-26-016105 Read from the filing’s XML Dispute this row |
| 2026-03-31 Filed 2026-03-31 | Michel Robert J Officer: Chief Financial Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 1,000 | 9.90 | 9,900Derived: shares × price per share. Exact value 9900.00. | 21,050 | Direct (D) | No | — | Open filing 0001493152-26-014397 Read from the filing’s XML Dispute this row |
| 2026-03-20 Filed 2026-03-24 | Jefferies John Officer: Chief Medical Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 3,656 | 0 | — | 21,272 | Direct (D) | No | F1
| Open filing 0001493152-26-012444 Read from the filing’s XML Dispute this row |
| 2026-03-20 Filed 2026-03-24 | Jefferies John Officer: Chief Medical Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 2,285 | 0 | — | 23,557 | Direct (D) | No | F2
| Open filing 0001493152-26-012444 Read from the filing’s XML Dispute this row |
| 2025-12-09 Filed 2025-12-11 | Michel Robert J Officer: Chief Financial Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 3,000 | 0 | — | 20,050 | Direct (D) | No | F1
| Open filing 0001493152-25-027230 Read from the filing’s XML Dispute this row |
| 2025-12-09 Filed 2025-12-11 | Feldschuh Jonathan Adam Director · Officer: Chief Scientific Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 18,000 | 0 | — | 53,908 | Direct (D) | No | F1
| Open filing 0001493152-25-027228 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 7,211 filings read, the latest filed 2026-11-13. Prior quarter ending 2026-06-30: 9,150 filings read.
Showing 1–15 of 15
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| THOMPSON SIEGEL WALMSLEY LLC Partly reported under another manager | 241,767 SH | 2,720 dollars | Unchanged Prior quarter: 241,767 | Open filing 0001008322-26-000012 Filed 2026-11-05 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 49,108 SH | 545,099 dollars | Higher by 277 Prior quarter: 48,831 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| BFC Planning, Inc. | 33,700 SH | 379,125 dollars | Lower by 3,000 Prior quarter: 36,700 | Open filing 0001420506-26-002645 Filed 2026-11-13 Dispute this row |
| RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager | 29,521 SH | 332,111 dollars | Higher by 100 Prior quarter: 29,421 | Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row |
| HRT FINANCIAL LP | 15,452 SH | 171 dollars | Not in the prior quarter’s filings read | Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P Partly reported under another manager | 15,000 SH | 168,750 dollars | Higher by 2,500 Prior quarter: 12,500 | Open filing 0001277890-26-000005 Filed 2026-11-13 Dispute this row |
| Crescent Grove Advisors, LLC | 12,423 SH | 139,759 dollars | Unchanged Prior quarter: 12,423 | Open filing 0000892712-26-000371 Filed 2026-10-21 Dispute this row |
| SBI Securities Co., Ltd. | 3,131 SH | 35,224 dollars | Unchanged Prior quarter: 3,131 | Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 3,087 SH | 34,729 dollars | Unchanged Prior quarter: 3,087 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 1,037 SH | 11,511 dollars | Unchanged Prior quarter: 1,037 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| OSAIC HOLDINGS, INC. Partly reported under another manager | 600 SH | 7,020 dollars | Higher by 100 Prior quarter: 500 | Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row |
| Godfrey Financial Associates, Inc. | 100 SH | 1,125 dollars | Not in the prior quarter’s filings read | Open filing 0002097943-26-000004 Filed 2026-11-10 Dispute this row |
| UBS Group AG Partly reported under another manager | 94 SH | 1,058 dollars | Lower by 78 Prior quarter: 172 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| Nuveen, LLC Partly reported under another manager | 41 SH | 480 dollars | Not in the prior quarter’s filings read | Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row |
| JPMORGAN CHASE CO Partly reported under another manager | 4 SH | 47 dollars | Lower by 2 Prior quarter: 6 | Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Aristides Capital LLC 41,689 SH
- SUSQUEHANNA INTERNATIONAL GROUP, LLP 27,131 SH
- BERTHEL, FISHER COMPANY FINANCIAL SERVICES, INC. 6,000 SH
- Tower Research Capital LLC (TRC) 305 SH
- WELLS FARGO COMPANY/MN 0 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
No Schedule 13D or 13G naming this issuer is in the store; this is not a statement that none were filed.
What was read
2,128,558 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 1 |
| 2016 | 204,322 |
| 2017 | 202,494 |
| 2018 | 202,048 |
| 2019 | 193,638 |
| 2020 | 144,184 |
| 2021 | 224,474 |
| 2022 | 51,728 |
| 2023 | 199,811 |
| 2024 | 209,823 |
| 2025 | 235,520 |
| 2026 | 254,737 |
Filings made before the SEC required XML are listed, not extracted.